Breaking News From Pharma & Bio Ingredients
Myriad Genetics Submits IND
Posted on 2004-12-28 15:44:00
Myriad Genetics, Inc. has submitted an Investigational New Drug (IND) application to the FDA to begin a Phase I human clinical trial with MPC-2130 (previously referred to as MPI-176716), a broad-acting inducer of apoptosis in cancer cells. The Phase I clinical study is designed to evaluate the safety and pharmacokinetic profile of MPC-2130 in patients with advanced metastatic tumors or blood cancers as well as refractory cancer that has progressed despite previous chemotherapy. In preclinical studies MPC-2130 has demonstrated significant cancer cell killing activity in ovarian cancer, prostate cancer and two lymphoma cell lines, Burkitt's lymphoma and T-cell lymphoma. MPC-2130 was also evaluated in xenograft mouse models of ovarian cancer and prostate cancer. The drug candidate reduced growth of ovarian cancer tumors by 61% relative to controls. MPC-2130 was also effective in demonstrating a significant reduction in tumor volumes in mice implanted with human prostate cancer.
Subscribe via RSS
